Liquidia Corp. (LQDA)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
$68.66+0.04%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
QuarterlyIQ Insights · LQDA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 56.6% |
| Our one-year growth estimate | diamond | 100.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 43.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has erratic recent earnings surprises and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 3 industry peers · Company calendar date is not available
LQDA — earnings miss
Dated 2026-08-12
of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant…
Why it matters: Being included can increase visibility. This may bring in new investors and impact the stock.
Supportive ifStock price increases by more than 10% within a month of inclusion.
Worry ifStock price remains flat or declines within a month of inclusion.
Why it matters: Liquidia has positive net income. This means it is making money and is healthy.
Supportive ifIn Q2, net income was over $52.9 million. This confirms they are profitable.
Worry ifIn Q2, net income fell below $52.9 million. This suggests possible financial problems.
Why it matters: The health care sector is slowing down. A return to growth could benefit Liquidia Corp.
Supportive ifHealth care sector revenue growth is speeding up to 10% or more.
Worry ifHealth care sector revenue growth keeps slowing down below current levels.
Why it matters: A drop in net income might show higher costs or slower sales, hurting profits.
Worry ifNet income falls below $70 million in Q3 2026.
Less concerning ifNet income remains above $70 million in Q3 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$246 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $506 loss on $10,000 · 5.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,566 loss on $10,000 · 35.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Better cash flow shows Liquidia is running its operations well. This means better financial health.
Supportive ifCash from operations exceeds $60 million in Q3 2026.
Worry ifCash from operations remains below $50 million in Q3 2026.
Why it matters: Positive net income shows Liquidia is making money. This means the company is healthy.
Supportive ifNet income for Q2 2026 is over $50 million. This shows Liquidia is doing well.
Worry ifNet income for Q2 2026 is negative or under $10 million. This raises concerns.
Why it matters: Progress in this key study may prove L606's potential. It could affect Liquidia's growth.
Supportive ifThere was a big announcement about patient enrollment in the Re-Spire study.
Worry ifDelays or setbacks in patient enrollment for the Re-Spire study.
Why it matters: Moving forward with the L606 study is important for Liquidia's product range. Success in enrollment shows strong interest in the study.
Supportive ifAt least 50% of targeted sites activated and enrolled by Q4 2026.
Worry ifLess than 30% of targeted sites activated by Q4 2026.
Why it matters: Strong sales growth signals continued adoption and market share gains for YUTREPIA. This supports Liquidia's growth strategy.
Supportive ifQ3 YUTREPIA sales growth exceeds 30% compared to Q2 2026.
Worry ifQ3 YUTREPIA sales growth is below 20% compared to Q2 2026.
Why it matters: High adjusted EBITDA shows Liquidia can keep making money. This is important for investor trust.
Supportive ifIn Q3, adjusted EBITDA is over $90 million.
Worry ifIn Q3, adjusted EBITDA is under $70 million.
Why it matters: A significant drop in cash could signal liquidity issues. Investors need to monitor this for financial health.
Worry ifCash and cash equivalents remain above $250 million.
Less concerning ifCash and cash equivalents drop below $250 million.